Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Next Previous
X
Search
Trial Profile

A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crovalimab (Primary) ; Crovalimab (Primary)
  • Indications Atypical Haemolytic Uraemic Syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms COMMUTE-p
  • Sponsors Roche

    • Most Recent Events

    • 13 Aug 2024 Planned End Date changed from 16 Sep 2029 to 20 Sep 2029.
    • 16 Jun 2023 Planned number of patients changed from 35 to 45.
    • 23 Aug 2022 Planned End Date changed from 16 Mar 2029 to 16 Sep 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top